Free Delivery Over $100
|
|
|||
|
||||
OverviewThe field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. Full Product DetailsAuthor: William R Strohl (Johnson & Johnson Biotechnology Center of Excellence) , Lila M Strohl (Medical Illustrator, USA) , W R StrohlPublisher: Elsevier Science & Technology Imprint: Woodhead Publishing Ltd Volume: 11 Dimensions: Width: 15.60cm , Height: 3.60cm , Length: 23.40cm Weight: 0.962kg ISBN: 9780081014271ISBN 10: 0081014279 Pages: 696 Publication Date: 30 October 2018 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: In stock  We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately. Table of ContentsReviewsAn excellent balance between readability and depth of material.... The book is well referenced and provides plentiful opportunities to continue subject-specific learing., mAbs Journal An excellent book describing many aspects of therapeutic antibody generation and the current market share of these drugs. It is an up-to-date evaluation of their production and clinical utility., Doody's Reviews An excellent balance between readability and depth of material.... The book is well referenced and provides plentiful opportunities to continue subject-specific learing., mAbs JournalAn excellent book describing many aspects of therapeutic antibody generation and the current market share of these drugs. It is an up-to-date evaluation of their production and clinical utility., Doody's Reviews An excellent balance between readability and depth of material... The book is well referenced and provides plentiful opportunities to continue subject-specific learing., mAbs Journal An excellent book describing many aspects of therapeutic antibody generation and the current market share of these drugs. It is an up-to-date evaluation of their production and clinical utility., Doody's Reviews Author InformationDr William R. Strohl is Vice President of Biologics Research at Janssen R&D Biotechnology Center of Excellence, and was previously a leader in Merck's efforts to discover therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. He has over 100 publications and several patents to his credit, and has edited two books. Tab Content 6Author Website:Countries AvailableAll regions |
||||
